HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TRANSTHERA-B

192.000

+19.30011.18%

Volume:7.86M

Turnover:1.53B

Market Cap:76.22B

PE:-244.68

High:217.000

Open:169.000

Low:168.900

Close:172.700

52wk High:679.500

52wk Low:20.200

Shares:397.00M

HK Float Shares:301.67M

Volume Ratio:1.20

T/O Rate:2.61%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.785

ROE:-39.08%

ROA:-21.10%

PB:120.06

PE(LYR):-244.68

PS:- -

Loading ...

Overview Company News Filings

HK Movers｜TRANSTHERA Soared Over 40%, Reaching A New High Since Listing, With A Surge Of Over 360% In The Past Seven Trading Days

Tiger Newspress

Hong Kong Stocks Midday Review | Hang Seng Index Rises 0.29% in Morning Session, CRO Concept Stocks Advance

TRANSTHERA-B Surges 77% Despite Zero Revenue and RMB 123 Million Loss in First Half, Market Cap Reaches HK$764 Billion

HK Movers | TransThera Sciences Stock Soars 60% After Receiving Chinese Regulatory Nod for Cancer Drug Human Trial

MT Newswires Live

Biotech Stocks Rebound. Transthera up 16%; Hightide up 13%; Clover Bio up over 9%; Alphamab up 8%; Zai Lab, Jacobio up over 6%; Mirxes up 5%

Tiger Newspress

BRIEF-Transthera Sciences (Nanjing) Inc Receives IND Approval From NMPA

TRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with Fulvestrant for Treatment-Failed HR-Positive/HER2-Negative or Low-Expressing Recurrent or Metastatic Breast Cancer Approved

Transthera Sciences Secures Phase II IND Approval for Tinengotinib and Fulvestrant Combination in Treating HR+/HER2- Metastatic Breast Cancer

Transthera Sciences (Nanjing) Inc - Ind Approval From Nmpa for Tinenogtinib Combination Phase Ii Trial

THOMSON REUTERS

HK Movers | Transthera-B, DualityBio-B Shares Surged About 16% After Being Added to the List of Securities for Southbound Trading

Tiger Newspress

TRANSTHERA-B Surges Nearly 11% in Early Trading to New Listing High as Company Joins Stock Connect

TRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with AKESO's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) Completes First Patient Dosing

TransThera Sciences Announces First Patient Dosed in Phase II Clinical Trial for Advanced Liver Cancer Treatment

Stock Track | TransThera Sciences Soars 8.53% Amid Broader Biotech Rally in Hong Kong

HK Movers | Biotech Stocks Surge With Cutia Therapeutics up 14%

Tiger Newspress

TRANSTHERA-B (02617) Selected for Inclusion in Hang Seng Index Series

TransThera Sciences Narrows Loss in H1

MT Newswires Live

BRIEF-TransThera Sciences (Nanjing) Inc Posts HY Loss Attributable RMB122.9 Million

Transthera Sciences (Nanjing) Inc - Hy Loss Attributable RMB122.9 Mln

THOMSON REUTERS

TRANSTHERA-B (02617) Included in Hang Seng Composite Index, Expected to Become Hong Kong Stock Connect Eligible Stock

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02617/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":192,"timestamp":1761120495743,"preClose":172.7,"halted":0,"volume":7860556,"delay":0,"floatShares":301666673,"shares":397000000,"eps":-0.784705739957569,"marketStatus":"Not Yet Opened","change":19.3,"latestTime":"10-22 16:08:15","open":169,"high":217,"low":168.9,"amount":1531610059,"amplitude":0.278518,"askPrice":192.1,"askSize":3000,"bidPrice":192,"bidSize":28500,"shortable":0,"etf":0,"ttmEps":-0.6769607682838692,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1761183000000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":172.7,"openAndCloseTimeList":[[1761096600000,1761105600000],[1761109200000,1761120000000]],"volumeRatio":1.195962,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":301666673,"roa":"-21.10%","roe":"-39.08%","lyrEps":-0.784706,"volumeRatio":1.195962,"shares":397000000,"dividePrice":0,"high":217,"amplitude":0.278518,"preClose":172.7,"low":168.9,"week52Low":20.2,"pbRate":"120.06","week52High":679.5,"institutionHeld":0,"latestPrice":192,"committee":0.809524,"eps":-0.784705739957569,"divideRate":0,"volume":7860556,"delay":0,"ttmEps":-0.6769607682838692,"open":169,"prevYearClose":13.15,"prevWeekClose":203,"prevMonthClose":141.2,"prevQuarterClose":141.2,"fiveDayClose":113.5,"twentyDayClose":147.7,"sixtyDayClose":38.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2025-10-21","current":-283.620572,"percent":0.035714,"low":-380.446233,"twenty":-184.903189,"median":-58.041658,"eighty":-41.987471,"high":-17.403134,"avg":-102.901877,"sd":82.505554,"marketCap":68544221219},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-21","current":-264.885138,"twenty":-184.903189,"median":-58.041658,"eighty":-41.987471,"marketCap":68544221219}],"updateTime":1761152556717},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1102741939","title":"HK Movers｜TRANSTHERA Soared Over 40%, Reaching A New High Since Listing, With A Surge Of Over 360% In The Past Seven Trading Days","url":"https://stock-news.laohu8.com/highlight/detail?id=1102741939","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102741939?lang=en_us&edition=fundamental","pubTime":"2025-09-15 13:17","pubTimestamp":1757913448,"startTime":"0","endTime":"0","summary":"$TRANSTHERA-B(02617)$ opened lower but rose sharply by 40%, reaching a new high since listing, with a surge of over 380% in the past seven trading days!","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"1119015110","title":"Hong Kong Stocks Midday Review | Hang Seng Index Rises 0.29% in Morning Session, CRO Concept Stocks Advance","url":"https://stock-news.laohu8.com/highlight/detail?id=1119015110","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119015110?lang=en_us&edition=fundamental","pubTime":"2025-09-15 12:06","pubTimestamp":1757909184,"startTime":"0","endTime":"0","summary":"The Hang Seng Index gained 0.29%, up 75 points to 26,463 points, while the Hang Seng Tech Index rose 1.11%. Hong Kong stocks recorded HK$162 billion in turnover during the morning session. CRO...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"71671f23af5254add17f6f727d43051d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["513600","159271","BK1189","02617","BK1184","YANG","HHImain","BK1501","BK1584","BK4614","HSI","BK1161","HSTECH","MCHmain","HSCEI","02833","MHImain","00376","06681","HSImain","07226"],"gpt_icon":1},{"id":"1193522292","title":"TRANSTHERA-B Surges 77% Despite Zero Revenue and RMB 123 Million Loss in First Half, Market Cap Reaches HK$764 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1193522292","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193522292?lang=en_us&edition=fundamental","pubTime":"2025-09-13 14:53","pubTimestamp":1757746419,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617.HK) opened with strong momentum on September 12, climbing throughout the trading session with an intraday high of HK$251.40 per share, representing a gain of over 130%. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2566195840","title":"HK Movers | TransThera Sciences Stock Soars 60% After Receiving Chinese Regulatory Nod for Cancer Drug Human Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2566195840","media":"MT Newswires Live","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566195840?lang=en_us&edition=fundamental","pubTime":"2025-09-12 11:58","pubTimestamp":1757649519,"startTime":"0","endTime":"0","summary":"Shares of $TransThera Sciences(02617)$ gained nearly 60% on Friday after a 21% rally in prior trading session.The biopharmaceutical company said it received Chinese regulatory approval to begin a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"db988090d391dada63985a8a8b176c17","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":1},{"id":"1165477251","title":"Biotech Stocks Rebound. Transthera up 16%; Hightide up 13%; Clover Bio up over 9%; Alphamab up 8%; Zai Lab, Jacobio up over 6%; Mirxes up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165477251","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165477251?lang=en_us&edition=fundamental","pubTime":"2025-09-12 09:48","pubTimestamp":1757641711,"startTime":"0","endTime":"0","summary":"Biotech stocks rebounded on Friday. Transthera up 16%; Hightide up 13%; Clover Bio up over 9%; Alphamab up 8%; Zai Lab, Jacobio up over 6%; Mirxes up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"dbb90568ab4fea5a8074bebd42fd3ce0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","09688","09966","01167","02617","02197"],"gpt_icon":0},{"id":"2566360002","title":"BRIEF-Transthera Sciences (Nanjing) Inc Receives IND Approval From NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2566360002","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566360002?lang=en_us&edition=fundamental","pubTime":"2025-09-10 23:11","pubTimestamp":1757517077,"startTime":"0","endTime":"0","summary":"BRIEF-Transthera Sciences (Nanjing) Inc Receives IND Approval From NMPASept 10 (Reuters) - TransThera Sciences (Nanjing) Inc 2617.HK:IND APPROVAL FROM NMPA FOR TINENOGTINIB COMBINATION PHASE II TRIALFurther company coverage: 2617.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nFWN3UX0GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1154237577","title":"TRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with Fulvestrant for Treatment-Failed HR-Positive/HER2-Negative or Low-Expressing Recurrent or Metastatic Breast Cancer Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=1154237577","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154237577?lang=en_us&edition=fundamental","pubTime":"2025-09-10 21:56","pubTimestamp":1757512578,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that its core product Tinengotinib (TT-00420) in combination with fulvestrant for the treatment of hormone receptor-positive (HR+) and human epidermal growth factor...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","HR","BK4225","BK4203","BK1161"],"gpt_icon":0},{"id":"2566602527","title":"Transthera Sciences Secures Phase II IND Approval for Tinengotinib and Fulvestrant Combination in Treating HR+/HER2- Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2566602527","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566602527?lang=en_us&edition=fundamental","pubTime":"2025-09-10 21:53","pubTimestamp":1757512397,"startTime":"0","endTime":"0","summary":"Transthera Sciences Secures Phase II IND Approval for Tinengotinib and Fulvestrant Combination in Treating HR+/HER2- Metastatic Breast Cancer. TransThera Sciences  Inc. has announced a significant regulatory milestone with the approval of a Phase II Investigational New Drug  by the National Medical Products Administration  of the People's Republic of China. This approval pertains to the clinical trial of Tinengotinib in combination with Fulvestrant, aimed at treating previously treated hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 negative or low expression  relapsed or metastatic breast cancer. The open-label, multicenter study will be conducted in China, focusing on evaluating the safety, efficacy, and pharmacokinetics of the treatment combination. This development marks a promising advancement in offering a new therapeutic option for patients resistant to conventional endocrine therapies.Disclaimer: This news brief was created by Public Technologies  u","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDLtmHZv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2566160233","title":"Transthera Sciences (Nanjing) Inc - Ind Approval From Nmpa for Tinenogtinib Combination Phase Ii Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2566160233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566160233?lang=en_us&edition=fundamental","pubTime":"2025-09-10 21:48","pubTimestamp":1757512080,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nFWN3UX0GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1174923850","title":"HK Movers | Transthera-B, DualityBio-B Shares Surged About 16% After Being Added to the List of Securities for Southbound Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174923850","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174923850?lang=en_us&edition=fundamental","pubTime":"2025-09-08 10:51","pubTimestamp":1757299883,"startTime":"0","endTime":"0","summary":"Transthera-B, DualityBio-B shares surged about 16% after being added to the list of securities for Southbound Trading.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8897b9b2c5acf19f1f0d138877ea54a6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","09606"],"gpt_icon":0},{"id":"1160465691","title":"TRANSTHERA-B Surges Nearly 11% in Early Trading to New Listing High as Company Joins Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1160465691","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160465691?lang=en_us&edition=fundamental","pubTime":"2025-09-08 10:20","pubTimestamp":1757298056,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) jumped over 10% in early trading, reaching an intraday high of HK$78, setting a new record since its listing. As of press time, the stock was up 10.54% to HK$69.75, with a...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","BK4614","BK1161","HSCEI","02617","YANG","07226"],"gpt_icon":1},{"id":"1153459765","title":"TRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with AKESO's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) Completes First Patient Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=1153459765","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153459765?lang=en_us&edition=fundamental","pubTime":"2025-09-04 22:46","pubTimestamp":1756997181,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the open-label, multi-center Phase II clinical studies of its core product Tinengotinib (TT-00420) in combination with AKESO Limited's Kantani® (Cadonilimab,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU0561508036.HKD","LU1720050803.USD","LU0417516902.SGD","BK1161","LU0348783233.USD","LU0417516571.SGD","LU0417516738.SGD","LU0348827113.USD","IE00BPRC5H50.USD","09926","LU0348735423.USD","LU2778985437.USD","IE00B543WZ88.USD","LU1169589451.USD","LU1169590202.USD","LU0348767384.USD","BK1574","PD","LU0634319403.HKD","LU2476274308.USD","LU2488822045.USD","LU0540923850.HKD","02617","BK4023","LU1794554557.SGD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0348766576.USD","LU2476274720.SGD"],"gpt_icon":1},{"id":"2564038133","title":"TransThera Sciences Announces First Patient Dosed in Phase II Clinical Trial for Advanced Liver Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2564038133","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564038133?lang=en_us&edition=fundamental","pubTime":"2025-09-04 22:34","pubTimestamp":1756996463,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. has announced the initiation of a Phase II clinical trial involving their Core Product, Tinengotinib , in combination with Akeso, Inc.'s cadonilimab  and ivonescimab  for the treatment of advanced hepatocellular carcinoma . The trial is an open-label, multicenter study conducted in China, aimed at evaluating the safety and efficacy of these combination therapies in patients who have not previously received systemic anticancer therapy for HCC or have failed prior standard treatments. The announcement noted that this clinical study marks the first dosing of a patient, while results from the trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL6Wxz7r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU0348783233.USD","LU0540923850.HKD","LU1720050803.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0348827113.USD","BK1161","LU0348735423.USD","02617","LU1794554557.SGD","LU0417516902.SGD","LU0348825331.USD","IE00BPRC5H50.USD","BK1574","LU2778985437.USD","LU0348767384.USD","LU2476274308.USD","LU0348784397.USD","LU0348766576.USD","LU0634319403.HKD","LU0417516571.SGD","LU2488822045.USD"],"gpt_icon":1},{"id":"1136230353","title":"Stock Track | TransThera Sciences Soars 8.53% Amid Broader Biotech Rally in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=1136230353","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136230353?lang=en_us&edition=fundamental","pubTime":"2025-08-29 10:40","pubTimestamp":1756435232,"startTime":"0","endTime":"0","summary":"TransThera Sciences (02617.HK) saw its stock soar by 8.53% during intraday trading on Friday, as part of a broader surge in Hong Kong's biotech sector. The significant uptick in TransThera's share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5f33b3b5eefd72d982b2d94c09297262","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02617"],"gpt_icon":0},{"id":"1183779957","title":"HK Movers | Biotech Stocks Surge With Cutia Therapeutics up 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183779957","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183779957?lang=en_us&edition=fundamental","pubTime":"2025-08-29 10:38","pubTimestamp":1756435121,"startTime":"0","endTime":"0","summary":"Biotech stocks surged in Hong Kong on Friday. Cutia Therapeutics rose 14%; Antengene rose 13%; HBM Holdings and TransThera Sciences rose 9%; RemeGen rose 8%; CARsgen Therapeutics rose 7%; WuXi...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5f33b3b5eefd72d982b2d94c09297262","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","02142","06996","02487","02269","02617","09995"],"gpt_icon":0},{"id":"1139681939","title":"TRANSTHERA-B (02617) Selected for Inclusion in Hang Seng Index Series","url":"https://stock-news.laohu8.com/highlight/detail?id=1139681939","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139681939?lang=en_us&edition=fundamental","pubTime":"2025-08-25 22:38","pubTimestamp":1756132713,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that following the quarterly review results published by Hang Seng Indexes Company Limited on August 22, 2025, the company has been selected for inclusion in various...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159271","HHImain","513600","02833","MHImain","HSI","MCHmain","BK1161","02617","HSImain"],"gpt_icon":0},{"id":"2562247307","title":"TransThera Sciences Narrows Loss in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2562247307","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562247307?lang=en_us&edition=fundamental","pubTime":"2025-08-25 21:33","pubTimestamp":1756128812,"startTime":"0","endTime":"0","summary":"TransThera Sciences  narrowed its attributable loss to 122.9 million yuan in the first half of 2025 from 160.4 million yuan a year prior, a Monday Hong Kong bourse filing said.Loss per share for the clinical-stage biopharmaceutical firm was 0.32 yuan, down from 0.42 yuan in the year-ago period.The firm did not record revenue in the period.Other income and gains, on the other hand, fell 65.1% to 3.6 million yuan in the six months from 10.4 million yuan a year prior, mainly due to a lower interest income from bank deposits and wealth management products, as well as a decline in government grants.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2562244773","title":"BRIEF-TransThera Sciences (Nanjing) Inc Posts HY Loss Attributable RMB122.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2562244773","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562244773?lang=en_us&edition=fundamental","pubTime":"2025-08-25 21:02","pubTimestamp":1756126931,"startTime":"0","endTime":"0","summary":"BRIEF-TransThera Sciences (Nanjing) Inc Posts HY Loss Attributable RMB122.9 MillionAug 25 (Reuters) - TransThera Sciences (Nanjing) Inc 2617.HK:HY LOSS ATTRIBUTABLE RMB122.9 MILLIONFurther company coverage: 2617.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2562413622","title":"Transthera Sciences (Nanjing) Inc - Hy Loss Attributable RMB122.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562413622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562413622?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:19","pubTimestamp":1756124370,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1103128195","title":"TRANSTHERA-B (02617) Included in Hang Seng Composite Index, Expected to Become Hong Kong Stock Connect Eligible Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1103128195","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103128195?lang=en_us&edition=fundamental","pubTime":"2025-08-22 20:48","pubTimestamp":1755866914,"startTime":"0","endTime":"0","summary":"On August 22nd, Hang Seng Indexes Company announced the quarterly review results of the Hang Seng Index Series as of June 30, 2025. TRANSTHERA-B (02617) was included in the Hang Seng Composite Index,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07226","02617","YANG","HSCEI","HSCI","HSTECH","BK4614"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}]}}